









Markets
/
Stocks
/
nasdaq-dnth
/

Dianthus Therapeutics Inc

DNTH

33.255USD

-0.775-2.28%

Market hours （ET）Quotes delayed by 15 min

1.07BMarket Cap

LossP/E TTM



Dianthus Therapeutics Inc

33.255

-0.775-2.28%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Dianthus Therapeutics Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite an average stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Dianthus Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

66 / 407

Overall Ranking

171 / 4617

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 14 analysts

Strong Buy

Current Rating

63.455

Target Price

+81.40%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Dianthus Therapeutics Inc Highlights

StrengthsRisks

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. Its product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile.

Growing

The company is in a growing phase, with the latest annual income totaling USD 6.24M.

Undervalued

The company’s latest PE is -10.40, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 40.30M shares, increasing 0.03% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 1.39M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 5.70, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 193.00K, representing a year-over-year decrease of 89.64%, while its net profit experienced a year-over-year decrease of 79.64%.

Score

Industry at a Glance

Previous score

5.70

Change



Financials

6.42

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.32

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.06

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Dianthus Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 6.72, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -10.40, which is -139.87% below the recent high of 4.15 and -223.65% above the recent low of -33.66.

Score

Industry at a Glance

Previous score

6.72

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 66/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 9.00, which is higher than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Dianthus Therapeutics Inc is 65.00, with a high of 100.00 and a low of 40.00.

Score

Industry at a Glance

Previous score

9.08

Change

-0.08

Support & Resistance

No Data

Analyst Rating

Based on 14 analysts

Strong Buy

Current Rating

63.455

Target Price

+86.47%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Dianthus Therapeutics Inc

DNTH

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 7.01, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 37.72 and the support level at 31.28, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.28

Change

-0.27

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.414

Neutral

RSI(14)

48.476

Neutral

STOCH(KDJ)(9,3,3)

53.273

Buy

ATR(14)

1.833

Low Volatility

CCI(14)

-38.311

Neutral

Williams %R

71.894

Sell

TRIX(12,20)

-0.193

Sell

StochRSI(14)

29.444

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

34.048

Sell

MA10

33.843

Sell

MA20

34.545

Sell

MA50

33.787

Sell

MA100

26.872

Buy

MA200

23.621

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 101.25%, representing a quarter-over-quarter decrease of 20.62%. The largest institutional shareholder is The Vanguard, holding a total of 1.45M shares, representing 3.63% of shares outstanding, with 15.49% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

4.45M

+1.69%

Fairmount Funds Management LLC

3.31M

+22.16%

Vestal Point Capital, LP

3.20M

+88.23%

RA Capital Management, LP

2.87M

Bain Capital Life Sciences Investors, LLC

2.48M

-7.71%

Octagon Capital Advisors LP

2.34M

Deep Track Capital LP

2.23M

-5.28%

Avidity Partners Management LP

1.74M

+1.28%

TCG Crossover Management, LLC

1.50M

The Vanguard Group, Inc.

Star Investors

1.45M

+30.41%

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 4.67, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.58. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.